Over the last 12 months, GeneDx Holdings insiders reported 1 buy totaling $11.1M and 5 sales totaling $1.1M across SEC Form 4 filings.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 10,501 | $60.77 | $638K | -9.1% | 3 tranches |
| Jun 16, 2026 | Feeley KevinCHIEF FINANCIAL OFFICER · O | ▼ Sale | 3,729 | $60.77 | $227K | -8.5% | 3 tranches |
| Jun 9, 2026 | Feeley KevinCHIEF FINANCIAL OFFICER · O | ▼ Sale | 1,266 | $53.77 | $68K | -3.4% | — |
| Jun 9, 2026 | Stueland KatherineCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 3,639 | $53.77 | $196K | -3.6% | — |
| Jun 5, 2026 | Casdin Capital, LLCD·10% | ▲ Buy | 200,000 | $55.55 | $11.1M | +5.7% | 2 tranches · indirect |
| Jun 1, 2026 | Feeley KevinCHIEF FINANCIAL OFFICER · O | ▼ Sale | 369 | $51.74 | $19K | -1% | — |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $WGS feed.